Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.

Patel NR, Cunoosamy DM, Fagerås M, Taib Z, Asimus S, Hegelund-Myrbäck T, Lundin S, Pardali K, Kurian N, Ersdal E, Kristensson C, Korsback K, Palmér R, Brown MN, Greenaway S, Siew L, Clarke GW, Rennard SI, Make BJ, Wise RA, Jansson P.

Int J Chron Obstruct Pulmon Dis. 2018 Mar 27;13:1009-1019. doi: 10.2147/COPD.S150576. eCollection 2018.

2.

AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure.

Pehrson R, Hegelund-Myrbäck T, Cunoosamy D, Asimus S, Jansson P, Patel N, Borde A, Lundin S.

J Pharmacol Exp Ther. 2018 Jun;365(3):567-572. doi: 10.1124/jpet.117.246132. Epub 2018 Mar 16.

PMID:
29549158
3.

Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848.

Delaney S, Biffen M, Maltby J, Bell J, Asimus S, Aggarwal A, Kraan M, Keeling D.

BMJ Open Respir Res. 2016 Feb 23;3(1):e000113. doi: 10.1136/bmjresp-2015-000113. eCollection 2016.

4.

PXR variants and artemisinin use in Vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisinin.

Piedade R, Schaeffeler E, Winter S, Asimus S, Schwab M, Ashton M, Burk O, Gil JP.

Antimicrob Agents Chemother. 2012 Apr;56(4):2153-7. doi: 10.1128/AAC.06009-11. Epub 2012 Jan 17.

5.

Artemisinin--a possible CYP2B6 probe substrate?

Asimus S, Ashton M.

Biopharm Drug Dispos. 2009 Jul;30(5):265-75. doi: 10.1002/bdd.665.

PMID:
19562679
6.

Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.

Veiga MI, Asimus S, Ferreira PE, Martins JP, Cavaco I, Ribeiro V, Hai TN, Petzold MG, Björkman A, Ashton M, Gil JP.

Eur J Clin Pharmacol. 2009 Apr;65(4):355-63. doi: 10.1007/s00228-008-0573-8. Epub 2008 Nov 1.

PMID:
18979093
7.

A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.

Elsherbiny DA, Asimus SA, Karlsson MO, Ashton M, Simonsson US.

J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):203-17. doi: 10.1007/s10928-008-9084-6. Epub 2008 Mar 19.

PMID:
18350255
8.

Artemisinin and CYP2A6 activity in healthy subjects.

Asimus S, Hai TN, Van Huong N, Ashton M.

Eur J Clin Pharmacol. 2008 Mar;64(3):283-92. Epub 2007 Dec 7.

PMID:
18064444
9.

The Vietnamese Khin population harbors particular N-acetyltransferase 2 allele frequencies.

Cavaco I, Asimus S, Peyrard-Janvid M, Ferreira PE, Veiga MI, Hai TN, Ribeiro V, Ashton M, Gil JP.

Clin Chem. 2007 Nov;53(11):1977-9. No abstract available.

10.

Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects.

Asimus S, Elsherbiny D, Hai TN, Jansson B, Huong NV, Petzold MG, Simonsson US, Ashton M.

Fundam Clin Pharmacol. 2007 Jun;21(3):307-16.

PMID:
17521300
11.

Supplemental Content

Loading ...
Support Center